The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

KNOXVILLE, Tenn. – Kalen DeBoer's message to Alabama football Saturday night after the Crimson Tide's 24-17 loss to Tennessee was simple. Look inward. Do some soul-searching. Get back to work.

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...